Research Paper Volume 16, Issue 3 pp 2563—2590
Integrative analysis confirms TPX2 as a novel biomarker for clinical implication, tumor microenvironment, and immunotherapy response across human solid tumors
Figure 6. Kaplan-Meier survival curves comparing the expression of TPX2 in pan-cancer from the TCGA database. (A) Kaplan–Meier OS curves of TPX2 in 11 cancer types; (B) Kaplan–Meier DSS curves of TPX2 in 11 cancer types; (C) Kaplan–Meier DFI curves of TPX2 in 8 cancer types; (D) Kaplan–Meier PFI curves of TPX2 in 11 cancer types. p-value < 0.05 was considered statistically significant.